Results 101 to 110 of about 350,390 (302)

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende, Emilien Petit, Young Woo Park, Sophie Tezenas du Montcel, James M. Joers, Jonathan M. DuBois, H. Moore Arnold, Michal Povazan, Ipek Özdemir, Guita Banan, Romain Valabregue, Philipp Ehses, Jennifer Faber, Chiadi U. Onyike, Peter B. Barker, Jeremy D. Schmahmann, Eva‐Maria Ratai, Sub H. Subramony, Thomas H. Mareci, Khalaf O. Bushara, Henry Paulson, Thomas Klockgether, Alexandra Durr, Tetsuo Ashizawa, Christophe Lenglet, Gülin Öz, READISCA Investigators   +26 more
wiley   +1 more source

Review of COVID-19 treatment

Journal of Research in Pharmacy Practice, 2020
Many contagious diseases, such as plague or cholera, played a role in changing the pathway of history. In this respect, although coronavirus was not as dangerous as novel diseases such as swine flu and Ebola, the spread and the power of coronavirus ...
Somayeh Sadeghi, Mahnaz Momenzadeh, Peiman Nasri, Mina Nickpour   +3 more
doaj   +1 more source

Current Status of Baricitinib as a Repurposed Therapy for COVID-19

Pharmaceuticals, 2021
The emergence of the COVID-19 pandemic has mandated the instant (re)search for potential drug candidates. In response to the unprecedented situation, it was recognized early that repurposing of available drugs in the market could timely save lives, by ...
Maha Saber-Ayad, Sarah Hammoudeh, Eman Abu-Gharbieh, Rifat Hamoudi, Hamadeh Tarazi, Taleb H. Al-Tel, Qutayba Hamid   +6 more
doaj   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Drug safety of frequently used drugs and substances for self-medication in COVID-19

Therapeutic Advances in Drug Safety, 2022
During the COVID-19 pandemic, the behavior of self-medication has increased. The dissemination of misleading information regarding the efficacy of certain drugs or substances for the prevention and treatment of COVID-19 has been the major contributing ...
Daniela Baracaldo-Santamaría, Santiago Pabón-Londoño, Luis Carlos Rojas-Rodriguez   +2 more
doaj   +1 more source

Update on Remdesivir in the Treatment of Novel Coronavirus Pneumonia

Progress in Microbes and Molecular Biology, 2023
Worldwide epidemic prevention and control remain under significant stress due to the global novel coronavirus disease 2019 (COVID-19) pandemic and the ongoing emergence of variants like Omicron.
Huang Feng, K. Vijaya Lakshmi, Chin Tat Ng, Murthy Sasikumar, Masita Arip, Masriana Hassan, Voon Kin Chin, Mogana Rajagopal, Omotayo Fatokun, N. Parvathi, Malarvili Selvaraja   +10 more
doaj   +1 more source

Point-of-care testing for disasters: needs assessment, strategic planning, and future design. [PDF]

, 2009
Objective evidence-based national surveys serve as a first step in identifying suitable point-of-care device designs, effective test clusters, and environmental operating conditions.
Bangs, Bulut, Cazacu, de la Hoz, Dighe, Diiulio, Ender, Farfel, Gerald J. Kost, Ginocchio, Grandjean, Grondhal, Hiransuthikul, Hurt, Ivers, Kazancioglu, Kost, Kost, Kost, Kost, Kost, Kristin N. Hale, Lam, Louie, Lupisan, Millie, MMWR, Nam K. Tran, Nicole L. Gentile, Nishiura, Pabbaraju, Qadri, Rajendran, Richard F. Louie, Schneider, Shaman, Shaman, Sinigalliano, T. Keith Brock, Tao, Thomas, Tyler K. Kitano, Uckay, Vernon, Vollaard   +44 more
core   +1 more source

Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 [PDF]

, 2020
Background and purpose Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported.
Boon, Paul, De Herdt, Veerle, Garrez, Ieme, Hemelsoet, Dimitri, Laureys, Guy, Raedt, Robrecht, Vonck, Kristl   +6 more
core   +2 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir

Medicina Clínica (English Edition), 2020
To determine the prevalence of potential interactions in COVID19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r.Cross-sectional and multicenter study with the participation of 2 hospitals.
Brandariz-Nuñez, David, Correas-Sanahuja, Marcelo, Guarc, Eva, Picón, Rafael, García, Bárbara, Gil, Rocío   +5 more
openaire   +3 more sources